Actelion says FDA accepts Macitentan for review.
Posted 20 January 2013 - 12:02 AM
Actelion has submitted an FDA application for macitentan for the treatment of pulmonary arterial hypertension (PAH), a condition characterized by abnormally high blood pressure in the arteries of the lungs. The review is expected to take 12 months. Reuters. 12/14/12. (Also see: Pulmonary Hypertension and Macitentan)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
ISN Assistant Webmaster
ISN Sclero Forums Manager
ISN News Manager
ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)